211 related articles for article (PubMed ID: 37500385)
1. [Treatment of lower risk myelodysplastic syndromes].
Park S
Bull Cancer; 2023 Nov; 110(11):1156-1161. PubMed ID: 37500385
[TBL] [Abstract][Full Text] [Related]
2. Next-generation therapy for lower-risk MDS.
Sébert M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
[TBL] [Abstract][Full Text] [Related]
5. Lower-risk myelodysplastic syndromes: Current treatment options for anemia.
Meunier M; Park S
EJHaem; 2022 Nov; 3(4):1091-1099. PubMed ID: 36467818
[TBL] [Abstract][Full Text] [Related]
6. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
Castelli R; Schiavon R; Rossi V; Deliliers GL
Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
[TBL] [Abstract][Full Text] [Related]
7. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
8. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
Santini V
Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
[TBL] [Abstract][Full Text] [Related]
10. Evolving therapies for lower-risk myelodysplastic syndromes.
Bewersdorf JP; Zeidan AM
Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
[TBL] [Abstract][Full Text] [Related]
11. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
12. Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes.
Kubasch AS; Platzbecker U
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31394818
[TBL] [Abstract][Full Text] [Related]
13. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
14. [Treatment for low-risk myelodysplastic syndromes].
Morita Y
Rinsho Ketsueki; 2018; 59(10):2050-2057. PubMed ID: 30305508
[TBL] [Abstract][Full Text] [Related]
15. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Volpe VO; Komrokji RS
Ther Adv Hematol; 2021; 12():2040620720986641. PubMed ID: 33505645
[TBL] [Abstract][Full Text] [Related]
16. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.
Fattizzo B; Versino F; Bortolotti M; Rizzo L; Riva M; Barcellini W
Eur J Haematol; 2023 May; 110(5):571-574. PubMed ID: 36727250
[TBL] [Abstract][Full Text] [Related]
17. SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
Volpe VO; Garcia-Manero G; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):168-177. PubMed ID: 36682988
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
19. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
20. Clinical decision-making and treatment of myelodysplastic syndromes.
Hellström-Lindberg ES; Kröger N
Blood; 2023 Dec; 142(26):2268-2281. PubMed ID: 37874917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
